COEPW
Wexford, PA 15090
US
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| DeSilva Tara | P-Purchase | 1,800 | $0.58 | 2024-01-12 |
| DeSilva Tara | P-Purchase | 466 | $0.56 | 2024-01-12 |
| Cogley Brian | P-Purchase | 5,000 | $0.67 | 2024-01-10 |
| Cogley Brian | 0 | — | 2024-01-10 | |
| Mehalick David | P-Purchase | 14,004 | $0.66 | 2024-01-08 |